Although Plotti et al. (34) reported that the use of HE4 in combination with CA125 and computed tomography (CT) could predict R0 resection in IDS and prognosis of ovarian cancer patients receiving NACT, 43.9% of the 114 patients had clear cell carcinoma whose biological characteristics are significantly different from HGSC (35). The gene discussed is WFDC2; the disease is clear cell adenocarcinoma.